Markets:

Overview

News

Currencies

International

Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

24.31 +1.30 (+5.65%)

Streaming Delayed Price Updated: 11:08 AM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 Next >

What This Immunome Sale Means a Day Before a Big FDA Milestone ↗

July 12, 2026

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.

Via The Motley Fool

Topics Regulatory Compliance

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗

April 04, 2026

This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

Via The Motley Fool

Where Immunome Stands With Analysts ↗

September 22, 2025

Via Benzinga

Where Immunome Stands With Analysts ↗

September 05, 2025

Via Benzinga

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’ ↗

September 05, 2025

Via Stocktwits

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Analyst Expectations For Immunome's Future ↗

November 08, 2024

Via Benzinga

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why Immunome Stock Surged Today ↗

December 15, 2025

The oncology specialist's targeted therapies could improve thousands of lives.

Via The Motley Fool

Which stocks are gapping on Monday? ↗

December 15, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Why Is IMNM Stock Rising Today? ↗

December 15, 2025

Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type...

Via Stocktwits

This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday ↗

September 22, 2025

Via Benzinga

This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

September 22, 2025

Via Benzinga

This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

August 22, 2025

Via Benzinga

Immunome (IMNM) Q2 Revenue Surges 382% ↗

August 06, 2025

Via The Motley Fool

These stocks are moving in today's after hours session ↗

June 30, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 30, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

January 29, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

3 Small-Cap Stocks With Big Growth Potential

December 13, 2024

Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.

Via MarketBeat

Topics Economy

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 01, 2024

Via Benzinga

Immunome Stock Sees RS Rating Jump To 91 ↗

August 20, 2024

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

Via Investor's Business Daily

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.